Spectral Medical (TSE:EDT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spectral Medical Inc. reported robust enrollment in the Tigris trial for its Polymyxin B Hemoperfusion treatment for septic shock, with completion expected by the end of 2024. Additionally, the company anticipates a positive impact from the Vantive-Carlyle Group transaction on the commercialization of its products.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.